Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 0.55 |
| ▸ | TSHR | P16473 | 3/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | CASP7 | P55210 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | TERT | O14746 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.38 |
| ▸ | S100B | P04271 | 1/20 | 0.37 |
| ▸ | CD44 | P16070 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29502024 | 1.00 | CYP3A4 (0.55) | CYP3A4TSHRMAPK1ALDH1A1CYP1A2 | |
| SCHEMBL29538146 | 0.92 | CYP3A4 (0.48) | CYP3A4TSHRMAPK1ALDH1A1CYP1A2 | |
| SCHEMBL457125 | 0.86 | CYP3A4 (0.52) | CYP3A4TSHRMAPK1ALDH1A1CYP1A2 | |
| SCHEMBL28606707 | 0.86 | CYP3A4 (0.60) | CYP3A4TSHRMAPK1ALDH1A1CYP1A2 | |
| SCHEMBL832391 | 0.86 | CYP3A4 (0.60) | CYP3A4TSHRMAPK1ALDH1A1CYP1A2 | |
| SCHEMBL1548535 | 0.86 | CYP3A4 (0.60) | CYP3A4TSHRMAPK1ALDH1A1CYP1A2 | |
| SCHEMBL29358157 | 0.86 | CYP3A4 (0.52) | CYP3A4TSHRMAPK1ALDH1A1CYP1A2 | |
| SCHEMBL9073257 | 0.83 | CYP3A4 (0.50) | CYP3A4TSHRMAPK1ALDH1A1CYP1A2 | |
| SCHEMBL249597 | 0.81 | CYP3A4 (0.48) | CYP3A4TSHRMAPK1ALDH1A1CYP1A2 | |
| SCHEMBL203096 | 0.81 | KDM1A (0.52) | CYP3A4TSHRMAPK1ALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112851493-B | Preparation method of 2,4, 5-trifluoro phenylacetic acid | 台州臻挚生物科技有限公司 | 2022-09-06 | — | — | CN | claimed |
| WO-2022099439-A1 | PREPARATION METHOD FOR 2,4,5-TRIFLUOROPHENYLACETIC ACID | 杭州臻挚生物科技有限公司 | 2022-05-19 | — | — | WO | claimed |
| CN-112851493-A | Preparation method of 2,4, 5-trifluorophenylacetic acid | 杭州臻挚生物科技有限公司 | 2021-05-28 | — | — | CN | claimed |
| US-20240327416-A1 | Further Substituted Triazolo Quinoxaline Derivatives | GRUENENTHAL GMBH (DE) | 2024-10-03 | — | — | US | disclosed |
| US-11981677-B2 | Further substituted triazolo quinoxaline derivatives | Grünenthal GmbH (DE) | 2024-05-14 | — | — | US | disclosed |
| EP-3532474-B1 | 4,5-ANNULATED 1,2,4-TRIAZOLONES | BAYER AG (DE) | 2024-03-27 | — | — | EP | disclosed |
| EP-4090660-B1 | QUINOXALINE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2024-01-31 | — | — | EP | disclosed |
| EP-3823970-B1 | FURTHER SUBSTITUTED TRIAZOLO QUINOXALINE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2024-01-03 | — | — | EP | disclosed |
| CN-114921391-B | 4, 5-cyclic 1,2, 4-triazolones | 拜耳股份有限公司 | 2024-01-02 | — | — | CN | disclosed |
| US-11787797-B2 | 4,5-annulated 1,2,4-triazolones | BAYER AKTIENGESELLSCHAFT (DE) | 2023-10-17 | — | — | US | disclosed |
| CN-112771046-B | Other substituted triazoloquinoxaline derivatives | 格吕伦塔尔有限公司 | 2023-09-19 | — | — | CN | disclosed |
| EP-2036891-A2 | Isoquinoline inhibitors of P38 | Vertex Pharmaceuticals Incorporated (US) | 2009-03-18 | — | — | EP | disclosed |
| EP-1077943-B1 | HETEROCYCLIC INHIBITORS OF P38 | VERTEX PHARMA (US) | 2008-12-17 | — | — | EP | disclosed |
| EP-1414455-B1 | ISOQUINOLINE INHIBITORS OF P38 | VERTEX PHARMA (US) | 2008-11-26 | — | — | EP | disclosed |
| US-7342013-B2 | Benzamides and related inhibitors of factor Xa | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-03-11 | — | — | US | disclosed |
| US-7314874-B2 | N-(5-bromo-2-pyridinyl)-(2-4-[(2-aminosulfonyl)phenyl]phenylcarbonylamino)phenylcarboxamide;modified amidine elements of high potency in vitro, excellent pharmacological and pharmaceutical properties in vivo | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-01-01 | — | — | US | disclosed |
| US-7314874-B2 | N-(5-bromo-2-pyridinyl)-(2-4-[(2-aminosulfonyl)phenyl]phenylcarbonylamino)phenylcarboxamide;modified amidine elements of high potency in vitro, excellent pharmacological and pharmaceutical properties in vivo | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-01-01 | — | — | US | disclosed |
| US-20070021472-A1 | N-(5-bromo-2-pyridinyl)-(2-4-[(2-aminosulfonyl)phenyl]phenylcarbonylamino)phenylcarboxamide; potent and highly selective inhibitors; coagulation disorders; antithrombotic agents; diagnostic reagents; good bioavailability and/or solubility | MILLENNIUM PHARMACEUTICALS, INC. | 2007-01-25 | — | — | US | disclosed |
| US-20070021472-A1 | N-(5-bromo-2-pyridinyl)-(2-4-[(2-aminosulfonyl)phenyl]phenylcarbonylamino)phenylcarboxamide; potent and highly selective inhibitors; coagulation disorders; antithrombotic agents; diagnostic reagents; good bioavailability and/or solubility | MILLENNIUM PHARMACEUTICALS, INC. | 2007-01-25 | — | — | US | disclosed |
| WO-2003024448-A2 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE, INC. (CA) | 2003-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240327416-A1 | Further Substituted Triazolo Quinoxaline Derivatives | NR3C1, GRK5, NR3C2 | CYP3A4 293/4885TSHR 209/4885MAPK1 821/4885 |
| US-11981677-B2 | Further substituted triazolo quinoxaline derivatives | NR3C1, GRK5, NR3C2 | CYP3A4 293/4885TSHR 209/4885MAPK1 821/4885 |
| US-11787797-B2 | 4,5-annulated 1,2,4-triazolones | CCNA1, CCNT1, CCND2 | CYP3A4 99/4885TSHR 1396/4885MAPK1 2327/4885 |
| US-20070021472-A1 | N-(5-bromo-2-pyridinyl)-(2-4-[(2-aminosulfonyl)phenyl]phenylcarbonylamino)phenylcarboxamide; potent and highly selective inhibitors; coagulation disorders; antithrombotic agents; diagnostic reagents; good bioavailability and/or solubility | F2, TFPI, PLG | CYP3A4 319/4885TSHR 2953/4885MAPK1 3997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.